Skip to content
HowShorted

Zynerba Pharmaceuticals, Inc. short interest in 2019

In 2019, Zynerba Pharmaceuticals, Inc.'s disclosed short interest ran from 12.42% of shares outstanding on 15 Jan 2019 to 25.56% on 31 Dec 2019, a change of +13.14 percentage points. The year's high was 25.56% on 31 Dec 2019 and its low 12.42% on 15 Jan 2019, averaging 18.70% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 18.15 days on 13 Dec 2019. Full history: Zynerba Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023

Aggregate net short position time series for Zynerba Pharmaceuticals, Inc. in 2019

2019 in figures

Start of year
12.42% (15 Jan 2019)
End of year
25.56% (31 Dec 2019)
Change
+13.14 pp
High
25.56% (31 Dec 2019)
Low
12.42% (15 Jan 2019)
Average
18.70%
Highest days to cover
18.15 (13 Dec 2019)
SEC filings marked
9

Every report in 2019

Zynerba Pharmaceuticals, Inc. short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 201912.42%5.66results (8-K)
31 Jan 201913.06%1.91
15 Feb 201917.08%2.12
28 Feb 201917.27%1.95
15 Mar 201914.02%5.4510-K filed, results (8-K)
29 Mar 201914.88%2.36
15 Apr 201917.14%1.00
30 Apr 201916.42%1.32
15 May 201918.68%1.2810-Q filed, results (8-K)
31 May 201914.64%1.23
14 Jun 201916.30%1.40
28 Jun 201918.70%2.35
15 Jul 201924.05%3.48
31 Jul 201924.13%3.39
15 Aug 201921.48%5.1410-Q filed, results (8-K)
30 Aug 201919.87%7.88
13 Sep 201918.46%6.39
30 Sep 201919.12%2.90
15 Oct 201922.53%9.51
31 Oct 201920.18%9.13
15 Nov 201919.74%7.5410-Q filed, results (8-K)
29 Nov 201921.71%13.80
13 Dec 201921.26%18.15
31 Dec 201925.56%7.70

See also: Zynerba Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.